BioSyent Releases Financial Results for Q2 and H1 2024
August 26, 2024 16:45 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30,...
BioSyent Declares Third Quarter 2024 Dividend
August 26, 2024 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent In-Licenses Endocrinology Product for Canada
June 12, 2024 09:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent Releases Financial Results for Q1 2024
May 16, 2024 18:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights...
BioSyent Declares Second Quarter 2024 Dividend
May 16, 2024 18:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend...
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024
May 09, 2024 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on...
BioSyent to Attend Planet MicroCap Showcase
April 23, 2024 17:45 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas,...
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
April 15, 2024 16:31 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton &...
FeraMAX® est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis neuf années consécutives
April 03, 2024 08:00 ET
|
BioSyent Inc.
Mississauga (Ontario), 03 avr. 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer...